Source: UNIV OF WISCONSIN submitted to NRP
DEVELOPMENT OF AN AFRICAN SWINE FEVER VIRUS SUBUNIT VACCINE
Sponsoring Institution
Agricultural Research Service/USDA
Project Status
ACTIVE
Funding Source
Reporting Frequency
Annual
Accession No.
0436806
Grant No.
(N/A)
Cumulative Award Amt.
(N/A)
Proposal No.
(N/A)
Multistate No.
(N/A)
Project Start Date
Aug 1, 2019
Project End Date
Jun 30, 2023
Grant Year
(N/A)
Program Code
[(N/A)]- (N/A)
Recipient Organization
UNIV OF WISCONSIN
21 N PARK ST STE 6401
MADISON,WI 53715-1218
Performing Department
(N/A)
Non Technical Summary
(N/A)
Animal Health Component
20%
Research Effort Categories
Basic
60%
Applied
20%
Developmental
20%
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
31135101040100%
Knowledge Area
311 - Animal Diseases;

Subject Of Investigation
3510 - Swine, live animal;

Field Of Science
1040 - Molecular biology;
Goals / Objectives
This project research project seeks to develop an African swine fever virus (ASFV) sub unit vaccine, using raccoon pox virus as vector, which can protect against the epidemiologically relevant strain Georgia 2007. Specific objectives include: 1. Develop an ASFV subunit vaccine candidate using racoon pox as a vector with the co-expression of several (6-18) immunogenetic viral proteins. 2. Assess immunogenicity and protective effect in swing against challenge.
Project Methods
The 5-10 most immunogenic African swine fever virus (ASFV) proteins will be selected based in results previously obtained by ARS, PIADC, where these proteins were identified by peptide scanning immune microarray. Based on this information, the corresponding recombinant plasmids will be commercially synthesized placing the selected ASFV proteins under the regulation of specific different promoters already tested in their efficacy in our laboratory. Recombinant viruses will be then produced using racoon pox vectored virus (RPVV) as templated. Once purified by successive purification steps, expression of ASFV recombinant proteins will be tested in vitro using monoclonal and monospecific polyclonal antibodies. Furthermore, recombinant RPVV developed in 2 will be evaluated in their ability to prevent disease after the challenge with ASFV Georgia07 strain. Pigs will be parenterally immunized and challenged following standard procedures at ARS, PIADC.